Seattle Genetics Stock Price, News & Analysis (NASDAQ:SGEN)

$59.05 0.35 (0.60 %)
(As of 11/21/2017 04:00 PM ET)
Previous Close$58.70
Today's Range$58.55 - $60.60
52-Week Range$45.31 - $72.75
Volume844,690 shs
Average Volume971,504 shs
Market Capitalization$8.50 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.4

About Seattle Genetics (NASDAQ:SGEN)

Seattle Genetics logoSeattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company's pipeline includes other clinical-stage ADC programs, such as ASG-22ME, SGN-LIV1A, SGN-CD19A, SGN-CD19B, SGN-CD123A, SGN-352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology, and SGN-2FF, which is a small molecule. It also has multiple preclinical and research-stage programs that employ its technologies, including SGN-CD48A and a preclinical ADC. ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Sector: Healthcare
  • Symbol: NASDAQ:SGEN
  • CUSIP: 81257810
  • Web: www.seattlegenetics.com
Debt:
  • Current Ratio: 4.06%
  • Quick Ratio: 3.66%
Sales & Book Value:
  • Annual Sales: $418.15 million
  • Price / Sales: 20.33
  • Book Value: $4.48 per share
  • Price / Book: 13.18
Profitability:
  • Trailing EPS: ($0.87)
  • Net Income: $-140,110,000.00
  • Net Margins: -26.53%
  • Return on Equity: -32.41%
  • Return on Assets: -24.77%
Misc:
  • Employees: 890
  • Outstanding Shares: 143,930,000
 

Frequently Asked Questions for Seattle Genetics (NASDAQ:SGEN)

What is Seattle Genetics' stock symbol?

Seattle Genetics trades on the NASDAQ under the ticker symbol "SGEN."

How were Seattle Genetics' earnings last quarter?

Seattle Genetics, Inc. (NASDAQ:SGEN) posted its earnings results on Thursday, October, 26th. The biotechnology company reported ($0.19) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.42) by $0.23. The biotechnology company earned $135.29 million during the quarter, compared to analysts' expectations of $112.76 million. Seattle Genetics had a negative net margin of 26.53% and a negative return on equity of 32.41%. The company's quarterly revenue was up 27.3% compared to the same quarter last year. During the same period last year, the company posted ($0.23) EPS. View Seattle Genetics' Earnings History.

When will Seattle Genetics make its next earnings announcement?

Seattle Genetics is scheduled to release their next quarterly earnings announcement on Wednesday, February, 7th 2018. View Earnings Estimates for Seattle Genetics.

Where is Seattle Genetics' stock going? Where will Seattle Genetics' stock price be in 2017?

21 brokerages have issued 1-year price objectives for Seattle Genetics' shares. Their forecasts range from $46.00 to $75.00. On average, they anticipate Seattle Genetics' stock price to reach $62.93 in the next twelve months. View Analyst Ratings for Seattle Genetics.

What are Wall Street analysts saying about Seattle Genetics stock?

Here are some recent quotes from research analysts about Seattle Genetics stock:

  • 1. Cann analysts commented, "Seattle Genetics and Astellas Pharma announced today dosing of the first patient in EV-103 study in combination with two different checkpoint inhibitors, for first- or second-line treatment of patients with locally advanced or metastatic urothelial cancer. We have not included any sales or earnings from enfortumab vedotin by 2021 due to its stage of development, but we are encouraged by this development program. Our financial outlook for Seattle Genetics’ revenue remains unchanged for 2017-21." (11/8/2017)
  • 2. According to Zacks Investment Research, "Seattle Genetics beat both earnings and sales estimates in the third quarter of 2017. Concurrently, the company raised 2017 revenues outlook.The company has upped its guidance for 2017 driven by a robust performance of Adcetris in the first half. We are also encouraged by the company’s efforts to expand the drug’s label. The company’s collaboration with Takeda for the global development and commercialization of Adcetris is encouraging. However, dependence on one product – Adcetris– for growth has its inherent risks. The recent label expansion of Merck’s Keytruda in the lymphoma indication is likely to increase competition. Though the company has multiple candidates in its pipeline, most of them are in early stages of development. The company’s shares have outperformed the industry year to date." (11/6/2017)
  • 3. Cantor Fitzgerald analysts commented, "The Phase III ECHELON-1 study in previously untreated patients with advanced classical Hodgkin lymphoma met its primary endpoint of modified PFS (82.1% versus 77.2% at two years)." (6/26/2017)
  • 4. Cowen and Company analysts commented, "SGEN announced this morning that following an interim safety look of 33A’s pivotal." (6/19/2017)

Who are some of Seattle Genetics' key competitors?

Who are Seattle Genetics' key executives?

Seattle Genetics' management team includes the folowing people:

  • Clay B. Siegall Ph.D., Chairman of the Board, President, Chief Executive Officer (Age 56)
  • Todd E. Simpson, Chief Financial Officer (Age 56)
  • Eric L. Dobmeier, Chief Operating Officer (Age 48)
  • Jean I. Liu J.D., Executive Vice President - Legal Affairs, General Counsel, Corporate Secretary (Age 48)
  • Darren S. Cline, Executive Vice President - Commercial (Age 52)
  • Jonathan G. Drachman M.D., Chief Medical Officer, Executive Vice President - Research and Development (Age 55)
  • Vaughn B. Himes Ph.D., Chief Technical Officer (Age 56)
  • Felix J. Baker Ph.D., Lead Independent Director (Age 47)
  • Srinivas Akkaraju M.D. Ph.D., Independent Director (Age 49)
  • David W. Gryska, Independent Director (Age 61)

Who owns Seattle Genetics stock?

Seattle Genetics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (10.78%), Capital International Investors (3.10%), Manning & Napier Advisors LLC (1.80%), Pictet Asset Management Ltd. (0.89%), Capital Guardian Trust Co. (0.74%) and Wasatch Advisors Inc. (0.71%). Company insiders that own Seattle Genetics stock include Clay B Siegall, Darren S Cline, Eric Dobmeier, Felix Baker, John A Orwin, Jonathan G Drachman, Marc E Lippman, Todd E Simpson and Vaughn B Himes. View Institutional Ownership Trends for Seattle Genetics.

Who sold Seattle Genetics stock? Who is selling Seattle Genetics stock?

Seattle Genetics' stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Baillie Gifford & Co., First Trust Advisors LP, Wells Fargo & Company MN, Candriam Luxembourg S.C.A., Lagoda Investment Management L.P., Wasatch Advisors Inc. and Canada Pension Plan Investment Board. Company insiders that have sold Seattle Genetics company stock in the last year include Clay B Siegall, Darren S Cline, Eric Dobmeier, Jonathan G Drachman, Marc E Lippman, Todd E Simpson and Vaughn B Himes. View Insider Buying and Selling for Seattle Genetics.

Who bought Seattle Genetics stock? Who is buying Seattle Genetics stock?

Seattle Genetics' stock was bought by a variety of institutional investors in the last quarter, including Manning & Napier Advisors LLC, Capital International Investors, Pictet Asset Management Ltd., Capital Guardian Trust Co., Capital Bank & Trust Co, Capital International Ltd. CA, Asset Management One Co. Ltd. and Capital International Inc. CA. Company insiders that have bought Seattle Genetics stock in the last two years include Felix Baker and John A Orwin. View Insider Buying and Selling for Seattle Genetics.

How do I buy Seattle Genetics stock?

Shares of Seattle Genetics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Seattle Genetics' stock price today?

One share of Seattle Genetics stock can currently be purchased for approximately $59.05.

How big of a company is Seattle Genetics?

Seattle Genetics has a market capitalization of $8.50 billion and generates $418.15 million in revenue each year. The biotechnology company earns $-140,110,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis. Seattle Genetics employs 890 workers across the globe.

How can I contact Seattle Genetics?

Seattle Genetics' mailing address is 21823 30th Dr SE, BOTHELL, WA 98021-3907, United States. The biotechnology company can be reached via phone at +1-425-5274000 or via email at [email protected]


MarketBeat Community Rating for Seattle Genetics (NASDAQ SGEN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  323 (Vote Outperform)
Underperform Votes:  382 (Vote Underperform)
Total Votes:  705
MarketBeat's community ratings are surveys of what our community members think about Seattle Genetics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Seattle Genetics (NASDAQ:SGEN)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 11 Hold Ratings, 9 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.38)
Consensus Price Target: $62.93 (6.58% upside)

Consensus Price Target History for Seattle Genetics (NASDAQ:SGEN)

Price Target History for Seattle Genetics (NASDAQ:SGEN)

Analysts' Ratings History for Seattle Genetics (NASDAQ:SGEN)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/13/2017Royal Bank Of CanadaBoost Price TargetOutperform -> Outperform$68.00 -> $69.00N/AView Rating Details
11/8/2017CannInitiated CoverageHoldN/AView Rating Details
10/31/2017Morgan StanleyBoost Price TargetOverweight$64.00 -> $69.00N/AView Rating Details
10/30/2017J P Morgan Chase & CoBoost Price TargetNeutral$55.00 -> $60.00N/AView Rating Details
10/29/2017Cowen and CompanyReiterated RatingHoldN/AView Rating Details
10/27/2017SunTrust Banks, Inc.Set Price TargetHold$52.00N/AView Rating Details
10/27/2017HC WainwrightReiterated RatingBuy$75.00N/AView Rating Details
10/27/2017Bank of America CorporationUpgradeUnderperform -> NeutralN/AView Rating Details
10/26/2017Jefferies Group LLCReiterated RatingBuy$53.00N/AView Rating Details
10/23/2017GuggenheimReiterated RatingBuy -> Buy$72.00N/AView Rating Details
10/20/2017Barclays PLCUpgradeEqual Weight -> Overweight$60.00 -> $70.00N/AView Rating Details
10/10/2017Cantor FitzgeraldSet Price TargetHold$46.00N/AView Rating Details
10/10/2017Oppenheimer Holdings, Inc.Initiated CoverageHoldN/AView Rating Details
10/6/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral -> Neutral$64.00N/AView Rating Details
6/26/2017William BlairReiterated RatingOutperformHighView Rating Details
6/27/2017Piper Jaffray CompaniesReiterated RatingNeutral$48.00HighView Rating Details
6/20/2017Needham & Company LLCReiterated RatingBuy$72.00LowView Rating Details
4/7/2017Leerink SwannBoost Price TargetOutperform$70.00 -> $74.00MediumView Rating Details
3/16/2017CIBCInitiated CoverageMarket Perform -> Market PerformLowView Rating Details
2/13/2017Credit Suisse GroupBoost Price TargetNeutral$62.00 -> $66.00N/AView Rating Details
1/5/2017Maxim GroupReiterated RatingReduceN/AView Rating Details
(Data available from 11/21/2015 forward)

Earnings

Earnings History and Estimates Chart for Seattle Genetics (NASDAQ:SGEN)

Earnings by Quarter for Seattle Genetics (NASDAQ:SGEN)

Earnings History by Quarter for Seattle Genetics (NASDAQ SGEN)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/7/2018($0.44)N/AView Earnings Details
10/26/2017Q3 2017($0.42)($0.19)$112.76 million$135.29 millionViewN/AView Earnings Details
7/27/2017Q2 2017($0.42)($0.39)$105.92 million$108.20 millionViewN/AView Earnings Details
4/27/2017Q1 2017($0.41)($0.42)$103.23 million$109.10 millionViewN/AView Earnings Details
2/9/2017Q416($0.34)($0.39)$106.49 million$105.30 millionViewListenView Earnings Details
10/27/2016Q316($0.29)($0.23)$4.34 million$106.30 millionViewListenView Earnings Details
7/26/2016Q216($0.32)($0.23)$94.56 million$95.40 millionViewListenView Earnings Details
4/28/2016Q116($0.09)($0.15)$116.49 million$111.15 millionViewListenView Earnings Details
2/9/2016Q415($0.20)($0.18)$88.00 million$93.50 millionViewN/AView Earnings Details
10/29/2015Q315($0.20)($0.21)$82.35 million$84.10 millionViewListenView Earnings Details
7/30/2015Q215($0.26)($0.38)$78.21 million$77.10 millionViewListenView Earnings Details
4/30/2015Q1($0.19)($0.17)$74.57 million$82.20 millionViewListenView Earnings Details
2/10/2015Q414($0.25)($0.22)$68.34 million$74.30 millionViewListenView Earnings Details
10/30/2014Q314($0.24)($0.13)$66.90 million$75.80 millionViewListenView Earnings Details
7/31/2014Q214($0.23)($0.14)$65.04 million$68.30 millionViewListenView Earnings Details
5/1/2014Q114($0.21)($0.13)$64.62 million$68.30 millionViewListenView Earnings Details
2/11/2014Q413($0.24)($0.13)$59.50 million$67.40 millionViewListenView Earnings Details
11/5/2013Q313($0.22)($0.19)$57.79 million$71.00 millionViewListenView Earnings Details
7/31/2013Q2 2013($0.20)($0.06)$58.12 million$773.60 millionViewListenView Earnings Details
5/7/2013Q1 2013($0.19)($0.14)$53.72 million$57.32 millionViewListenView Earnings Details
2/12/2013Q4 2012($0.10)($0.09)$57.21 million$63.90 millionViewListenView Earnings Details
11/7/2012Q312($0.14)($0.12)$52.79 million$49.83 millionViewN/AView Earnings Details
8/8/2012($0.15)($0.15)ViewN/AView Earnings Details
5/8/2012($0.11)($0.11)ViewN/AView Earnings Details
2/13/2012($0.31)($0.24)ViewN/AView Earnings Details
11/3/2011($0.46)($0.35)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Seattle Genetics (NASDAQ:SGEN)
2017 EPS Consensus Estimate: ($1.51)
2018 EPS Consensus Estimate: ($1.38)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.39)($0.39)($0.39)
Q2 20173($0.44)($0.28)($0.37)
Q3 20174($0.47)($0.19)($0.34)
Q4 20174($0.50)($0.23)($0.41)
Q1 20181($0.42)($0.42)($0.42)
Q2 20181($0.33)($0.33)($0.33)
Q3 20181($0.25)($0.25)($0.25)
Q4 20181($0.38)($0.38)($0.38)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Seattle Genetics (NASDAQ:SGEN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Seattle Genetics (NASDAQ SGEN)

Insider Ownership Percentage: 34.70%
Institutional Ownership Percentage: 96.93%
Insider Trades by Quarter for Seattle Genetics (NASDAQ:SGEN)
Institutional Ownership by Quarter for Seattle Genetics (NASDAQ:SGEN)

Insider Trades by Quarter for Seattle Genetics (NASDAQ SGEN)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/17/2017Eric DobmeierCOOSell35,000$58.25$2,038,750.00View SEC Filing  
11/15/2017Eric DobmeierCOOSell9,600$57.80$554,880.00View SEC Filing  
11/15/2017Marc E. LippmanDirectorSell3,000$58.07$174,210.00View SEC Filing  
11/10/2017Clay B. SiegallInsiderSell18,832$58.00$1,092,256.00View SEC Filing  
11/1/2017Todd E. SimpsonCFOSell39,385$60.91$2,398,940.35View SEC Filing  
10/11/2017Clay B SiegallInsiderSell18,832$61.18$1,152,141.76View SEC Filing  
9/11/2017Clay B. SiegallInsiderSell18,832$53.49$1,007,323.68View SEC Filing  
9/8/2017Vaughn B. HimesInsiderSell10,000$53.22$532,200.00View SEC Filing  
9/6/2017Darren S. ClineEVPSell5,024$51.94$260,946.56View SEC Filing  
9/6/2017Todd E. SimpsonCFOSell9,638$52.00$501,176.00View SEC Filing  
8/31/2017Darren S. ClineEVPSell7,569$52.51$397,448.19View SEC Filing  
8/31/2017Eric DobmeierCOOSell25,000$52.24$1,306,000.00View SEC Filing  
8/28/2017Clay B. SiegallCEOSell25,506$47.89$1,221,482.34View SEC Filing  
8/28/2017Darren S. ClineEVPSell1,788$47.89$85,627.32View SEC Filing  
8/28/2017Eric DobmeierCOOSell5,343$47.89$255,876.27View SEC Filing  
8/28/2017Jonathan G. DrachmanCMOSell8,502$47.89$407,160.78View SEC Filing  
8/28/2017Todd E. SimpsonCFOSell4,937$47.89$236,432.93View SEC Filing  
8/28/2017Vaughn B. HimesInsiderSell6,377$47.89$305,394.53View SEC Filing  
8/24/2017Jonathan G. DrachmanCMOSell10,000$47.54$475,400.00View SEC Filing  
8/7/2017Clay B. SiegallInsiderSell10,413$48.91$509,299.83View SEC Filing  
8/7/2017Darren S. ClineEVPSell6,000$49.19$295,140.00View SEC Filing  
7/27/2017Jonathan G. DrachmanCMOSell10,000$54.54$545,400.00View SEC Filing  
7/5/2017Clay B. SiegallCEOSell10,423$51.98$541,787.54View SEC Filing  
6/22/2017Jonathan G DrachmanCMOSell10,000$64.01$640,100.00View SEC Filing  
6/5/2017Clay B. SiegallInsiderSell10,423$65.21$679,683.83View SEC Filing  
4/5/2017Clay B SiegallInsiderSell14,465$62.99$911,150.35View SEC Filing  
3/31/2017Vaughn B HimesInsiderSell10,000$62.75$627,500.00View SEC Filing  
3/6/2017Clay B SiegallCEOSell14,465$68.04$984,198.60View SEC Filing  
2/6/2017Clay B SiegallInsiderSell14,465$61.54$890,176.10View SEC Filing  
1/6/2017Clay B. SiegallInsiderSell14,465$57.89$837,378.85View SEC Filing  
12/13/2016Darren S. ClineEVPSell10,000$63.38$633,800.00View SEC Filing  
12/8/2016Eric DobmeierCOOSell12,500$65.92$824,000.00View SEC Filing  
12/7/2016Vaughn B. HimesInsiderSell30,000$65.32$1,959,600.00View SEC Filing  
11/8/2016Felix BakerDirectorBuy382,500$59.36$22,705,200.00View SEC Filing  
11/7/2016Clay B. SiegallCEOSell14,465$58.43$845,189.95View SEC Filing  
11/7/2016Marc E. LippmanDirectorSell1,000$57.75$57,750.00View SEC Filing  
11/3/2016Felix BakerDirectorBuy1,030,629$56.13$57,849,205.77View SEC Filing  
11/1/2016Jonathan G. DrachmanCMOSell3,418$51.74$176,847.32View SEC Filing  
10/6/2016Clay B. SiegallInsiderSell14,465$54.41$787,040.65View SEC Filing  
9/22/2016Jonathan G DrachmanCMOSell2,249$56.75$127,630.75View SEC Filing  
9/14/2016Eric DobmeierCOOSell22,918$54.04$1,238,488.72View SEC Filing  
9/13/2016Felix BakerDirectorBuy447,311$50.71$22,683,140.81View SEC Filing  
9/8/2016Clay B. SiegallInsiderSell31,269$50.08$1,565,951.52View SEC Filing  
9/8/2016Felix BakerDirectorBuy414,016$48.43$20,050,794.88View SEC Filing  
8/23/2016Eric DobmeierCOOSell12,589$48.00$604,272.00View SEC Filing  
8/22/2016Clay B. SiegallInsiderSell23,381$46.59$1,089,320.79View SEC Filing  
8/22/2016Eric DobmeierCOOSell5,411$46.59$252,098.49View SEC Filing  
8/22/2016Vaughn B. HimesEVPSell3,991$46.59$185,940.69View SEC Filing  
8/8/2016Clay B. SiegallInsiderSell11,660$47.19$550,235.40View SEC Filing  
7/27/2016Clay B. SiegallInsiderSell4,042$45.20$182,698.40View SEC Filing  
7/6/2016Clay B. SiegallCEOSell7,618$40.56$308,986.08View SEC Filing  
6/6/2016Clay B SiegallCEOSell22,083$43.59$962,597.97View SEC Filing  
6/2/2016Darren S ClineEVPSell3,366$42.07$141,607.62View SEC Filing  
5/27/2016Clay B SiegallCEOSell48,660$40.41$1,966,350.60View SEC Filing  
5/24/2016Clay B SiegallCEOSell8,400$40.09$336,756.00View SEC Filing  
5/23/2016Clay B SiegallCEOSell6,700$40.12$268,804.00View SEC Filing  
5/17/2016Clay B SiegallCEOSell7,618$35.16$267,848.88View SEC Filing  
4/25/2016Clay B SiegallCEOSell800$40.00$32,000.00View SEC Filing  
4/5/2016Clay B SiegallCEOSell7,618$36.12$275,162.16View SEC Filing  
3/22/2016Clay B SiegallCEOSell15,236$35.52$541,182.72View SEC Filing  
3/21/2016Clay B SiegallCEOSell4,282$35.01$149,912.82View SEC Filing  
3/17/2016Felix BakerDirectorBuy124,065$31.85$3,951,470.25View SEC Filing  
3/16/2016Felix BakerDirectorBuy1,349,237$32.10$43,310,507.70View SEC Filing  
3/15/2016Felix BakerDirectorBuy661,093$32.08$21,207,863.44View SEC Filing  
3/14/2016Felix BakerDirectorBuy118,941$33.77$4,016,637.57View SEC Filing  
3/11/2016Felix BakerDirectorBuy694,666$32.46$22,548,858.36View SEC Filing  
3/8/2016Felix BakerDirectorBuy502,523$22.66$11,387,171.18View SEC Filing  
3/2/2016Felix BakerDirectorBuy675,922$31.77$21,474,041.94View SEC Filing  
3/1/2016Felix BakerDirectorBuy24,200$31.24$756,008.00View SEC Filing  
2/29/2016Felix BakerDirectorBuy251,722$30.39$7,649,831.58View SEC Filing  
2/26/2016Felix BakerDirectorBuy314,508$29.55$9,293,711.40View SEC Filing  
2/22/2016Felix BakerDirectorBuy1,001,471$29.63$29,673,585.73View SEC Filing  
2/17/2016Felix BakerDirectorBuy1,269,147$30.43$38,620,143.21View SEC Filing  
2/12/2016John A. OrwinDirectorBuy2,000$28.33$56,660.00View SEC Filing  
12/15/2015Vaughn B. HimesEVPSell40,500$39.94$1,617,570.00View SEC Filing  
12/3/2015Clay B. SiegallCEOSell3,720$39.99$148,762.80View SEC Filing  
11/20/2015Felix BakerDirectorBuy329,358$43.94$14,471,990.52View SEC Filing  
11/17/2015Clay B SiegallCEOSell87,473$45.40$3,971,274.20View SEC Filing  
11/11/2015Darren S ClineSVPSell5,769$45.68$263,527.92View SEC Filing  
11/10/2015Felix BakerDirectorBuy934,624$42.95$40,142,100.80View SEC Filing  
11/9/2015Felix BakerDirectorBuy507,300$43.76$22,199,448.00View SEC Filing  
11/6/2015Eric DobmeierCOOSell17,452$42.50$741,710.00View SEC Filing  
11/6/2015Felix BakerDirectorBuy417,924$41.94$17,527,732.56View SEC Filing  
11/5/2015David W GryskaDirectorSell10,000$43.57$435,700.00View SEC Filing  
11/4/2015Clay B. SiegallCEOSell3,718$43.14$160,394.52View SEC Filing  
10/5/2015Clay B. SiegallCEOSell3,718$41.30$153,553.40View SEC Filing  
9/3/2015Clay B. SiegallCEOSell3,718$40.12$149,166.16View SEC Filing  
8/20/2015Clay B. SiegallCEOSell31,754$42.02$1,334,303.08View SEC Filing  
8/20/2015Darren S. ClineSVPSell2,231$42.02$93,746.62View SEC Filing  
8/20/2015Eric DobmeierCOOSell8,548$42.02$359,186.96View SEC Filing  
8/20/2015Jonathan G. DrachmanCMOSell4,462$42.02$187,493.24View SEC Filing  
8/20/2015Todd E. SimpsonCFOSell5,825$42.02$244,766.50View SEC Filing  
8/20/2015Vaughn B. HimesEVPSell5,997$42.02$251,993.94View SEC Filing  
7/6/2015Clay B SiegallCEOSell3,718$46.94$174,522.92View SEC Filing  
6/3/2015Clay B SiegallCEOSell3,718$45.72$169,986.96View SEC Filing  
5/21/2015Felix BakerDirectorBuy950,886$42.49$40,403,146.14View SEC Filing  
5/8/2015Eric DobmeierCOOSell17,074$40.38$689,448.12View SEC Filing  
5/7/2015Felix BakerDirectorBuy1,032,664$35.56$36,721,531.84View SEC Filing  
3/10/2015Felix BakerDirectorBuy285,036$34.66$9,879,347.76View SEC Filing  
3/9/2015Felix BakerDirectorBuy275,717$34.66$9,556,351.22View SEC Filing  
3/4/2015Felix BakerDirectorBuy448,841$34.84$15,637,620.44View SEC Filing  
2/25/2015Felix BakerDirectorBuy281,115$33.92$9,535,420.80View SEC Filing  
1/6/2015Clay B SiegallCEOSell16,804$31.80$534,367.20View SEC Filing  
12/16/2014Felix BakerDirectorBuy2,883,378$31.86$91,864,423.08View SEC Filing  
12/10/2014Felix BakerDirectorBuy1,247,896$33.82$42,203,842.72View SEC Filing  
12/9/2014Felix BakerDirectorBuy128,430$34.16$4,387,168.80View SEC Filing  
12/8/2014Felix BakerDirectorBuy465,316$32.93$15,322,855.88View SEC Filing  
11/12/2014Vaughn B HimesEVPSell10,000$37.52$375,200.00View SEC Filing  
11/10/2014Felix BakerDirectorBuy1,653,925$34.56$57,159,648.00View SEC Filing  
9/4/2014Clay B SiegallCEOSell5,600$42.54$238,224.00View SEC Filing  
8/12/2014Clay B SiegallCEOSell11,200$40.38$452,256.00View SEC Filing  
8/11/2014Clay B SiegallCEOSell2,700$40.05$108,135.00View SEC Filing  
6/13/2014Felix BakerDirectorBuy216,595$39.92$8,646,472.40View SEC Filing  
6/10/2014Clay B SiegallCEOSell11,200$40.14$449,568.00View SEC Filing  
6/9/2014Felix BakerDirectorBuy546,252$38.16$20,844,976.32View SEC Filing  
6/4/2014Felix BakerDirectorBuy281,963$34.86$9,829,230.18View SEC Filing  
5/16/2014Felix BakerDirectorBuy189,611$34.07$6,460,046.77View SEC Filing  
4/3/2014Clay SiegallCEOSell5,600$43.34$242,704.00View SEC Filing  
2/18/2014Clay SiegallCEOSell100,000$51.97$5,197,000.00View SEC Filing  
1/21/2014Eric DobmeierCOOSell56,010$47.92$2,683,999.20View SEC Filing  
1/16/2014Jonathan DrachmanCMOSell1,201$45.75$54,945.75View SEC Filing  
12/16/2013Felix BakerDirectorBuy407,078$39.66$16,144,713.48View SEC Filing  
12/5/2013Felix BakerDirectorBuy1,005,901$43.19$43,444,864.19View SEC Filing  
10/1/2013Clay B SiegallCEOSell2,000$43.87$87,740.00View SEC Filing  
9/10/2013Eric DobmeierCOOSell42,000$46.40$1,948,800.00View SEC Filing  
9/5/2013Eric DobmeierCOOSell75,000$42.64$3,198,000.00View SEC Filing  
9/3/2013Clay B SiegallCEOSell102,000$43.90$4,477,800.00View SEC Filing  
9/3/2013David W GryskaDirectorSell10,000$42.48$424,800.00View SEC Filing  
8/27/2013Todd SimpsonCFOSell37,763$41.45$1,565,276.35View SEC Filing  
8/19/2013Clay SiegallCEOSell7,653$40.91$313,084.23View SEC Filing  
8/19/2013Eric DobmeierCOOSell3,328$40.91$136,148.48View SEC Filing  
8/19/2013Vaughn HimesEVPSell1,736$40.91$71,019.76View SEC Filing  
8/1/2013Clay B SiegallCEOSell2,000$40.03$80,060.00View SEC Filing  
7/12/2013Todd E SimpsonCFOSell92,527$37.45$3,465,136.15View SEC Filing  
7/1/2013Clay B SiegallCEOSell2,000$32.59$65,180.00View SEC Filing  
6/14/2013Srinivas AkkarajuDirectorSell5,000$32.75$163,750.00View SEC Filing  
6/13/2013Vaughn B HimesEVPSell10,000$32.11$321,100.00View SEC Filing  
6/3/2013Clay B SiegallCEOSell2,000$33.88$67,760.00View SEC Filing  
5/10/2013Srinivas AkkarajuDirectorSell17,500$37.17$650,475.00View SEC Filing  
3/6/2013Eric DobmeierCOOSell100,000$29.68$2,968,000.00View SEC Filing  
2/25/2013David W GryskaDirectorSell10,000$27.17$271,700.00View SEC Filing  
2/1/2013Clay B SiegallCEOSell2,000$29.61$59,220.00View SEC Filing  
1/15/2013Thomas C ReynoldsInsiderSell125,079$28.00$3,502,212.00View SEC Filing  
11/1/2012Clay B SiegallCEOSell8,250$25.51$210,457.50View SEC Filing  
9/4/2012Clay B SiegallCEOSell8,250$26.54$218,955.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Seattle Genetics (NASDAQ SGEN)

Source:
DateHeadline
Seattle Genetics, Inc. – Value Analysis (NASDAQ:SGEN) : November 15, 2017Seattle Genetics, Inc. – Value Analysis (NASDAQ:SGEN) : November 15, 2017
finance.yahoo.com - November 18 at 11:53 AM
Seattle Genetics, Inc. (SGEN) Raised to "C" at TheStreetSeattle Genetics, Inc. (SGEN) Raised to "C" at TheStreet
www.americanbankingnews.com - November 18 at 7:40 AM
Seattle Genetics, Inc. (SGEN) Director Marc E. Lippman Sells 3,000 SharesSeattle Genetics, Inc. (SGEN) Director Marc E. Lippman Sells 3,000 Shares
www.americanbankingnews.com - November 17 at 10:49 PM
Eric Dobmeier Sells 9,600 Shares of Seattle Genetics, Inc. (SGEN) StockEric Dobmeier Sells 9,600 Shares of Seattle Genetics, Inc. (SGEN) Stock
www.americanbankingnews.com - November 17 at 10:26 PM
Seattle Genetics, Inc. (SGEN) COO Sells $2,038,750.00 in StockSeattle Genetics, Inc. (SGEN) COO Sells $2,038,750.00 in Stock
www.americanbankingnews.com - November 17 at 10:26 PM
Seattle Genetics, Inc. (SGEN) Given Consensus Rating of "Hold" by BrokeragesSeattle Genetics, Inc. (SGEN) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - November 16 at 6:02 AM
Seattle Genetics, Inc. breached its 50 day moving average in a Bearish Manner : SGEN-US : November 14, 2017Seattle Genetics, Inc. breached its 50 day moving average in a Bearish Manner : SGEN-US : November 14, 2017
finance.yahoo.com - November 15 at 8:24 AM
Seattle Genetics, Inc. (SGEN) Insider Clay B. Siegall Sells 18,832 SharesSeattle Genetics, Inc. (SGEN) Insider Clay B. Siegall Sells 18,832 Shares
www.americanbankingnews.com - November 14 at 11:02 PM
Seattle Genetics Adcetris Gets FDA Nod for Label ExpansionSeattle Genetics' Adcetris Gets FDA Nod for Label Expansion
www.nasdaq.com - November 14 at 7:49 AM
Seattle Genetics' Adcetris Gets FDA Nod for Label ExpansionSeattle Genetics' Adcetris Gets FDA Nod for Label Expansion
finance.yahoo.com - November 14 at 7:49 AM
Seattle Genetics (SGEN) Announces FDA Approval of ADCETRISSeattle Genetics (SGEN) Announces FDA Approval of ADCETRIS
www.streetinsider.com - November 10 at 12:06 PM
Report: Exploring Fundamental Drivers Behind Tronox, Ameren, GrubHub, Patterson Companies, AVEO Pharmaceuticals, and Seattle Genetics – New Horizons, Emerging Trends, and Upcoming DevelopmentsReport: Exploring Fundamental Drivers Behind Tronox, Ameren, GrubHub, Patterson Companies, AVEO Pharmaceuticals, and Seattle Genetics – New Horizons, Emerging Trends, and Upcoming Developments
finance.yahoo.com - November 10 at 12:06 PM
$109.73 Million in Sales Expected for Seattle Genetics, Inc. (SGEN) This Quarter$109.73 Million in Sales Expected for Seattle Genetics, Inc. (SGEN) This Quarter
www.americanbankingnews.com - November 10 at 9:46 AM
Seattle Genetics, Inc. (SGEN) Expected to Post Quarterly Sales of $109.73 MillionSeattle Genetics, Inc. (SGEN) Expected to Post Quarterly Sales of $109.73 Million
www.americanbankingnews.com - November 10 at 5:44 AM
Seattle Genetics (SGEN) Announces FDA Approval of ADCETRIS - StreetInsider.comSeattle Genetics (SGEN) Announces FDA Approval of ADCETRIS - StreetInsider.com
www.streetinsider.com - November 9 at 6:19 PM
Seattle Genetics and Astellas Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic ...Seattle Genetics and Astellas Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic ...
www.businesswire.com - November 9 at 1:16 PM
Seattle Genetics and Astellas Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic Urothelial CancerSeattle Genetics and Astellas Initiate Phase 1b Trial of Enfortumab Vedotin in Combination with Immune Checkpoint Inhibitor Therapies in Locally Advanced or Metastatic Urothelial Cancer
finance.yahoo.com - November 9 at 1:16 PM
Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing Mycosis Fungoides (MF)Seattle Genetics Announces FDA Approval of ADCETRIS® (Brentuximab Vedotin) for Primary Cutaneous Anaplastic Large Cell Lymphoma (pcALCL) and CD30-Expressing Mycosis Fungoides (MF)
finance.yahoo.com - November 9 at 1:15 PM
Seattle Genetics, Inc. (SGEN) Coverage Initiated at CannSeattle Genetics, Inc. (SGEN) Coverage Initiated at Cann
www.americanbankingnews.com - November 8 at 3:40 PM
Q4 2017 Earnings Estimate for Seattle Genetics, Inc. (SGEN) Issued By Oppenheimer HoldingsQ4 2017 Earnings Estimate for Seattle Genetics, Inc. (SGEN) Issued By Oppenheimer Holdings
www.americanbankingnews.com - November 6 at 8:24 AM
Seattle Genetics Target of Unusually High Options Trading (SGEN)Seattle Genetics Target of Unusually High Options Trading (SGEN)
www.americanbankingnews.com - November 6 at 2:28 AM
Stock Traders Buy High Volume of Put Options on Seattle Genetics (SGEN)Stock Traders Buy High Volume of Put Options on Seattle Genetics (SGEN)
www.americanbankingnews.com - November 5 at 3:18 AM
Seattle Genetics (SGEN) Submits sBLA to FDA for ADCETRIS in Frontline Advanced Hodgkin Lymphoma - StreetInsider.comSeattle Genetics (SGEN) Submits sBLA to FDA for ADCETRIS in Frontline Advanced Hodgkin Lymphoma - StreetInsider.com
www.streetinsider.com - November 4 at 2:43 PM
Todd E. Simpson Sells 39,385 Shares of Seattle Genetics, Inc. (SGEN) StockTodd E. Simpson Sells 39,385 Shares of Seattle Genetics, Inc. (SGEN) Stock
www.americanbankingnews.com - November 3 at 8:35 PM
Zacks Investment Research Lowers Seattle Genetics, Inc. (SGEN) to HoldZacks Investment Research Lowers Seattle Genetics, Inc. (SGEN) to Hold
www.americanbankingnews.com - November 3 at 1:44 PM
Seattle Genetics (SGEN) to Present Data from Broad ADCETRIS Program at ASHSeattle Genetics (SGEN) to Present Data from Broad ADCETRIS Program at ASH
www.streetinsider.com - November 2 at 8:43 AM
Seattle Genetics Submits SBLA To FDA For ADCETRIS In Frontline Hodgkin LymphomaSeattle Genetics Submits SBLA To FDA For ADCETRIS In Frontline Hodgkin Lymphoma
www.rttnews.com - November 2 at 8:43 AM
Seattle Genetics to Present Data from Broad ADCETRIS® (Brentuximab Vedotin) Development Program at ASH 2017Seattle Genetics to Present Data from Broad ADCETRIS® (Brentuximab Vedotin) Development Program at ASH 2017
finance.yahoo.com - November 2 at 8:43 AM
Seattle Genetics, Inc.: Double-Digit Revenue Growth, but the Best Is Yet to ComeSeattle Genetics, Inc.: Double-Digit Revenue Growth, but the Best Is Yet to Come
finance.yahoo.com - November 2 at 8:43 AM
Earnings Review and Free Research Report: Biogen’s Adjusted EPS Surged 25.1%Earnings Review and Free Research Report: Biogen’s Adjusted EPS Surged 25.1%
finance.yahoo.com - November 2 at 8:43 AM
Seattle Genetics Submits Supplemental Biologics License Application to FDA for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin LymphomaSeattle Genetics Submits Supplemental Biologics License Application to FDA for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma
finance.yahoo.com - November 2 at 8:43 AM
FY2017 Earnings Forecast for Seattle Genetics, Inc. (SGEN) Issued By Cantor FitzgeraldFY2017 Earnings Forecast for Seattle Genetics, Inc. (SGEN) Issued By Cantor Fitzgerald
www.americanbankingnews.com - November 1 at 9:21 AM
Featured Company News - FDA Granted Orphan Drug Designation to Merrimacks MM-121 for Treatment of Heregulin Positive Non-Small Cell Lung CancerFeatured Company News - FDA Granted Orphan Drug Designation to Merrimack's MM-121 for Treatment of Heregulin Positive Non-Small Cell Lung Cancer
finance.yahoo.com - November 1 at 8:37 AM
Seattle Genetics, Inc. (SGEN) Raised to Buy at Zacks Investment ResearchSeattle Genetics, Inc. (SGEN) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - October 31 at 12:42 PM
Seattle Genetics, Inc. (SGEN) Price Target Increased to $69.00 by Analysts at Morgan StanleySeattle Genetics, Inc. (SGEN) Price Target Increased to $69.00 by Analysts at Morgan Stanley
www.americanbankingnews.com - October 31 at 9:55 AM
IBD Rating Upgrades: Seattle Genetics Flashes Improved Price StrengthIBD Rating Upgrades: Seattle Genetics Flashes Improved Price Strength
finance.yahoo.com - October 31 at 9:23 AM
Seattle Genetics, Inc. (SGEN) Price Target Increased to $60.00 by Analysts at J P Morgan Chase & CoSeattle Genetics, Inc. (SGEN) Price Target Increased to $60.00 by Analysts at J P Morgan Chase & Co
www.americanbankingnews.com - October 30 at 10:57 AM
Seattle Genetics, Inc. (SGEN) Given a $52.00 Price Target by SunTrust Banks, Inc. AnalystsSeattle Genetics, Inc. (SGEN) Given a $52.00 Price Target by SunTrust Banks, Inc. Analysts
www.americanbankingnews.com - October 28 at 10:14 AM
HC Wainwright Reiterates "Buy" Rating for Seattle Genetics, Inc. (SGEN)HC Wainwright Reiterates "Buy" Rating for Seattle Genetics, Inc. (SGEN)
www.americanbankingnews.com - October 28 at 12:26 AM
Seattle Genetics (SGEN) vs. The Competition Financial ComparisonSeattle Genetics (SGEN) vs. The Competition Financial Comparison
www.americanbankingnews.com - October 27 at 11:26 PM
BofA/Merrill Lynch Upgrades Seattle Genetics (SGEN) to Neutral - StreetInsider.comBofA/Merrill Lynch Upgrades Seattle Genetics (SGEN) to Neutral - StreetInsider.com
www.streetinsider.com - October 27 at 10:56 PM
EARNINGS SUMMARY: Details of Seattle Genetics Inc. Q3 Earnings ReportEARNINGS SUMMARY: Details of Seattle Genetics Inc. Q3 Earnings Report
www.rttnews.com - October 27 at 5:44 PM
Seattle Genetics (SGEN) Q3 2017 Results - Earnings Call TranscriptSeattle Genetics (SGEN) Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - October 27 at 5:44 PM
[$$] Seattle Genetics May See Significant Upside[$$] Seattle Genetics May See 'Significant Upside'
finance.yahoo.com - October 27 at 5:44 PM
Seattle Genetics, Inc. to Host Earnings CallSeattle Genetics, Inc. to Host Earnings Call
finance.yahoo.com - October 27 at 5:44 PM
Seattle Genetics Reports Third Quarter 2017 Financial ResultsSeattle Genetics Reports Third Quarter 2017 Financial Results
finance.yahoo.com - October 27 at 5:44 PM
Seattle Genetics tops Street 3Q forecastsSeattle Genetics tops Street 3Q forecasts
finance.yahoo.com - October 27 at 5:44 PM
Versartis Drops on Q3 Numbers, Hires Adviser -- Biotech MoversVersartis Drops on Q3 Numbers, Hires Adviser -- Biotech Movers
finance.yahoo.com - October 27 at 5:44 PM
Edited Transcript of SGEN earnings conference call or presentation 26-Oct-17 8:30pm GMTEdited Transcript of SGEN earnings conference call or presentation 26-Oct-17 8:30pm GMT
finance.yahoo.com - October 27 at 5:44 PM
Seattle Genetics, Inc. (SGEN) Announces Quarterly  Earnings ResultsSeattle Genetics, Inc. (SGEN) Announces Quarterly Earnings Results
www.americanbankingnews.com - October 26 at 9:26 PM

Social Media

Financials

Chart

Seattle Genetics (NASDAQ SGEN) Chart for Tuesday, November, 21, 2017
Loading chart…

This page was last updated on 11/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.